Adaptive Mechanisms In GRown up ObeSity Study (AMIGROS)

Vastra Gotaland Region

Status: Enrolling

Conditions: Obesity; Type 2 Diabetes

Treatments: Device: Subcutaneous microdialysis

Study type: Observational

Funder types: Other

Identifiers

NCT06065930

2023-02051-02

Details and patient eligibility

About

The investigator recently showed that the glycan-binding adipokine galectin-1 increased during overfeeding and that galectin-1 independently could predict type 2 diabetes. Further, the molecules that induce insulin release in the fasting state when blood glucose is normal remain elusive. It is possible that galectin-1 is involved in adaptive mechanisms in adipose tissue in obese subjects.

Full description

The investigator will define adaptive mechanisms in adipose tissue associated with galectin-1 in obese insulin-sensitive (Ob-IS) subjects compared with obese insulin-resistant (Ob-IR) subjects and lean healthy controls. Further, the investigator will study molecules secreted from adipose tissue that might trigger insulin secretion when blood glucose is normal.

The investigator hypothesizes that Ob-IS subjects keep fatty acid levels normal through an adaptive response in adipose tissue that involves up-regulation of galectin-1 for dampening of immune cell activity and stimulation of lipolysis.

Enrollment: 45 estimated patients

Sex: All

Ages: 40 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Men and women of age: 40.0 - 70.0 years

2. BMI: 18.0 - 25.0 kg/m2 (lean subjects) and BMI 30.0 - 38.0 kg/m2 (Ob-IS and Ob-IR)

3. Fasting insulin < 9.0 mU/l (lean and Ob-IS subjects) and fasting insulin > 9.0 mU/l (Ob-IR)

4. Fasting glucose < 6.1 mmol/l

5. Body temperature < 37.5°C

6. First-degree relative with known T2D in Ob-IR

7. Weight stable ± 5 kg < 3 months before screening

8. Fluent in Swedish and can follow given instructions

9. Consent given to participate

   Exclusion Criteria:

10. First-degree relative with known T2D in lean or Ob-IS subjects

11. Alcohol intake > 10 units/week or known high alcohol intake < 10 years back in time

12. Daily use of cigarettes or daily frequent use of smokeless tobacco not enabling the participant to suspend nicotine during a visit at the research center without getting abstinent

13. Regular physical activity corresponding to Saltin-Gimby level 4

14. Special diet eg Atkins or 5:2 for weight reduction. Vegetarian food accepted if duration > 1 year

15. Impaired fasting glucose (IFG) (venous fasting plasma glucose 6.1-6.9 mmol/l)

16. Type 2 diabetes according to ADA criteria

17. Ongoing or previous ischemic heart disease, eg angina pectoris, unstable angina or previous myocardial infarction treated with platelet inhibitors or non vitamin-K oral anticoagulants

18. Heart failure (NYHA II-IV) or cardiac arrhytmia that needs medical treatment

19. Previous cerebral infarction or transitory ischemic episodes (TIA) treated with platelet inhibitors or other anticoagulants

20. Peripheral arterial insufficiency eg claudication

21. Hypertension >170/105 mmHg at screening or more than one class of drugs for treatment of known hypertension

22. Lipid disorder defined as fasting serum triglycerides > 5.0 mmol/l or serum cholesterol > 7.5 mmol/l

23. Hematologic diseases such as anemia not being substituted (Hb < 130 g/l in males and Hv < 120 g/l in females) or disease causing bleeding disorder

24. Renal failure defined as absolute estimated glomerular filtration rate (eGFRcreatinine) < 60 ml/min/1.73 m2

25. Hypothyroidism defined as TSH > 4.0 mIE/l and symptoms

26. Liver disease e.g. hepatitis B, cirrhosis or conditions where AST or ALT are > 2 times UNL

27. Systemic inflammatory disease e.g. rheumatoid arthritis, ulcerative cholitis or Chrons disease. Celiac disease, dyspepsia or IBS are excepted

28. Chronic bronchitis or chronic obstructive pulmonary with disease symptoms

29. Previous pancreatitis or other disease in pancreas that needs treatment

30. Migraine elicited by stress

31. Spinal insufficiency causing inconvenience lying in supine position during the study day

32. Drug addiction interfering with the study procedures

33. Psychiatric insufficiency interfering with the study procedures

34. Medication with potential to affect adipose tissue metabolism that can not be stopped 10 days before the study days

35. Treatment with beta-blockers

36. Less than three months from previous use of antibiotics

37. Cancer disease < 5 years since diagnosis

38. Physical examination or laboratory results indicating that participation in the study is inappropriate

39. Pregnancy or intention to be pregnant during the study

40. Shift work > 1 time per week that might interfere with the circadian rhytm

41. Other reasons that causes the PI to believe that participation is inappropriate

Trial design

45 participants in 3 patient groups

Obese insulin-sensitive subjects (Ob-IS)

Description:

Obese Insulin Sensitive subjects (BMI \> 30 kg/m2, fasting insulin \< 9.0 mU/l and fasting plasma glucose \< 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.

Treatment:

Device: Subcutaneous microdialysis

Obese insulin-resistant subjects (Ob-IR)

Description:

Obese Insulin Resistant subjects (BMI \> 30 kg/m2, fasting insulin \> 9.0 mU/l and fasting plasma glucose \< 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.

Treatment:

Device: Subcutaneous microdialysis

Lean healthy controls (Lean)

Description:

Lean healthy controls (BMI \< 25 kg/m2, fasting insulin \< 9.0 mU/l and fasting plasma glucose \< 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.

Treatment:

Device: Subcutaneous microdialysis